Latest Conference Coverage

Advances in Multifaceted Drug Approaches for Dementia in Movement Disorders: Charbel Moussa, MBBS, PhD

The associate professor of neurology at Georgetown University Medical Center talked about innovative treatments for dementia in movement disorders that target multiple mechanisms to effectively modify the disease. [WATCH TIME: 7 minutes]

NeuroVoices: Kelly Papesh, DNP, APRN, FNP-BC, on Understanding Patient Silence for Movement Disorder Concerns in the Clinical Setting

The executive director of the Association of Movement Disorder Advanced Practice Providers talked about a recent survey highlighting why patients with movement disorders may withhold critical health information from their providers.

Emerging Promise of Tyrosine Kinase Inhibitors in Neurological Disease Treatment: Charbel Moussa, MBBS, PhD

The associate professor of neurology at Georgetown University Medical Center talked about the potential of tyrosine kinase inhibitors in treating neurodegenerative diseases. [WATCH TIME: 7 minutes]

The Importance of Open Communication in Patient Care: Kelly Papesh, DNP, APRN, FNP-BC

The executive director of the Association of Movement Disorder Advanced Practice Providers discussed how effective patient care in movement disorders can lead to better management and treatment outcomes. [WATCH TIME: 4 minutes]

Improving Medication Management and Education of Parkinson Disease in Hospital Settings: Patricia Clark, CNP

The nurse practitioner at the Cleveland Clinic talked about findings from a recent study focused on enhancing medication management and education for patients with Parkinson disease. [WATCH TIME: 5 minutes]

The Challenges and Innovations in Parkinson Treatment: Michael Soileau, MD, FAAN

The movement disorder specialist at Texas Movement Disorder Specialists talked about the complexities and advancements in treating Parkinson disease, emphasizing the need for strategic and aggressive treatment approaches despite administrative burdens. [WATCH TIME: 5 minutes]

Importance of Informed Patient Conversations Regarding Subcutaneous Infusion Pumps for PD: Anvi Gadani, MD

The assistant clinical professor of medicine at Medstar Georgetown University Hospital highlighted the need for clinicians to maintain informed, open-minded discussions about therapeutic options. [WATCH TIME: 2 minutes]

Cladribine and Other Agents in Aging Multiple Sclerosis

Impacts of Health Care-Related Social Determinants of Health

Assessing Long-Term Benefit of Eptinezumab for Chronic Migraine: Amaal Starling, MD, FAHS, FAAN

The associate professor of neurology at Mayo Clinic College of Medicine discussed findings from a post-hoc analysis of the phase 3 PREVAIL study presented at AHS 2024 assessing eptinezumab in patients with chronic migraine. [WATCH TIME: 4 minutes]

Building a Vibrant Community of Neurology Educators: Tracey Milligan, MD, MS, FAAN, FANA, FAES

The professor and chair of neurology at New York Medical College discussed her extensive involvement in neurology education and the recent efforts to enhance neurology education through various programs. [WATCH TIME: 5 minutes]

Cleveland Clinic's Parkinson Disease Inpatient Program Improves Patient Outcomes

The Cleveland Clinic Foundation Parkinson's Inpatient Program is a proactive, multidisciplinary intervention aimed to enhance the quality and safety of care for hospitalized patients with Parkinson disease.

Episode 118: Gaining Patient Perspectives on the Impact of Narcolepsy

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Anne Marie Morse, DO, FAAN. [LISTEN TIME: 18 minutes]

Managing Wearing Off Effect in High-Efficacy Disease-Modifying Therapies

Pitolisant Reduces Excessive Daytime Sleepiness and Fatigue in Myotonic Dystrophy Type 1

Additional data of a phase 2 study presented at the 2024 SLEEP Annual Meeting demonstrated that pitolisant significantly improved in secondary end points among patients with myotonic dystrophy type 1.

Treatment Decisions With Stable MS

Istradefylline Shows Promising Effects as Treatment for Tremor in Parkinson Disease

Istradefylline led to significant reductions in tremor and motor symptoms in patients with Parkinson disease over 24 weeks.

Continuous Subcutaneous Apomorphine Infusion Sustains Efficacy in Phase 3 InfusON Trial

Advancements in Multidisciplinary Parkinson Disease Treatment: Michael Soileau, MD, FAAN

The movement disorder specialist at Texas Movement Disorder Specialists talked about a comprehensive panel discussion that highlighted the evolution of Parkinson disease treatment. [WATCH TIME: 4 minutes]

Enhancing Hospital Care for Patients With Parkinson Disease: Patricia Clark, CNP

The nurse practitioner at the Cleveland Clinic talked about a specialized program involving nurse practitioners that aims to improve inpatient care quality and safety for patients with Parkinson disease. [WATCH TIME: 5 minutes]

NeuroVoices: Sanjay R. Patel, MD, MS, on Advances in Pharmaceutical Treatment for Sleep Apnea

The director of the Center for Sleep and Cardiovascular Outcomes Research at University of Pittsburgh talked about a phase 3 trial assessing a pharmaceutical treatment, AD109, in sleep apnea.

Phase 2 SUNRISE-PD Trial to Test Investigational Bezisterim as Disease-Modifying Therapy for Parkinson

Bezisterim has shown potential in improving non-motor symptoms like fatigue and sleep issues, with promising results from previous studies.

Small-Scale Trial of Pimavanserin Highlights Modified Functional Status Questionnaire as Reliable Tool for Parkinson Disease Psychosis

Modified Functional Status Questionnaire, an assessment of activities of daily living, includes several different notable domains, including quality of interaction, social activity, and psychological function.

Amyloid and Non-Amyloid Advanced Therapeutics in Dementia: R. Scott Turner, PhD, MD, FANA, FAAN

The director of the Memory Disorders Program at Georgetown University talked about newly approved anti-amyloid antibodies that show significant promise in slowing Alzheimer disease progression. [WATCH TIME: 5 minutes]

Better Safety Profile Observed With Istradefylline Over Amantadine Extended-Release and COMT Inhibitors

Although the data used predated 2019, istradefylline was associated with a statistically significant lower odds of the overall incidence of treatment-emergent adverse events than other adjunctive therapies for Parkinson disease.

Patients With Essential Tremor Report High Levels of Dissatisfaction With Treatment Options

In a large-scale analysis. 70% of patients with essential tremor and 70% of undiagnosed patients reported dissatisfaction with the therapeutic options available to treat their condition.

Disease-Modifying Therapies for Dementia in Movement Disorders: Charbel Moussa, MBBS, PhD

The associate professor of neurology at Georgetown University Medical Center talked about disease-modifying therapies for movement disorder-related dementia that aim to address the underlying mechanisms of the disease. [WATCH TIME: 5 minutes]

Overcoming Barriers in Communication for Patient Disclosure in Movement Disorders: Kelly Papesh, DNP, APRN, FNP-BC

The executive director of the Association of Movement Disorder Advanced Practice Providers talked about the need for improved communication and trust of the patient-provider relationship in the field of movement disorders. [WATCH TIME: 3 minutes]

Advanced Therapeutic Options for Parkinson Disease and Essential Tremor: Anvi Gadani, MD

The assistant clinical professor of medicine at Medstar Georgetown University Hospital talked about her presentation at ATMRD where she covered various advanced therapies for managing Parkinson disease and essential tremor. [WATCH TIME: 5 minutes]

Role of Sleep Chronotype, Circadian Rhythm in Neurocognitive Health: Ashley Curtis, PhD

The assistant professor at the University of South Florida provided perspective on the influence of circadian rhythm in neurocognitive health and the possibilities of screening for circadian rhythm issues for large-scale clinical trials. [WATCH TIME: 4 minutes]